AbbVie has reported that a subcutaneous infusion of Parkinson's disease candidate ABBV-951 was more effective than standard oral therapy in a phase 3 trial, paving the way for regulatory filings.

AbbVie has filed for approval of its therapy for Parkinson's disease, ABBV-951, which promises continuous control of symptoms and would be an alternative to current drugs that often fail to ...

AbbVie ABBV announced that the FDA has approved its subcutaneous administered drug ABBV-951 to treat motor fluctuations in adult patients with advanced Parkinson's disease (PD). The drug will be ...